Financial Performance - The company's revenue for Q3 2023 was ¥93,685,931.29, a decrease of 39.32% compared to the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥8,194,972.00, representing a decline of 138.56% year-on-year[4]. - The cash flow from operating activities showed a significant drop of 83.28%, totaling ¥15,331,465.02 year-to-date[4]. - The operating profit decreased by 66% to ¥2,574.35 million, attributed to lower sales prices and a decline in gross margin[9]. - In Q3 2023, the company's net profit was CNY 20,063,872.53, a decrease of 68.9% compared to CNY 64,516,609.20 in the same period last year[23]. - Operating profit for the period was CNY 25,743,482.41, down 66.1% from CNY 76,036,036.95 in the previous year[23]. - Total revenue from operating activities was CNY 284,772,830.69, a decline of 34.0% compared to CNY 431,487,306.00 in Q3 2022[25]. - The company reported a net cash flow from operating activities of CNY 15,331,465.02, significantly lower than CNY 91,674,963.47 in the same quarter last year[26]. - Research and development expenses were CNY 16,959,260.69, down 20.5% from CNY 21,362,731.92 in the previous year[23]. - The company incurred financial expenses of CNY 4,592,922.14, compared to a financial income of CNY 2,690,174.89 in the same period last year[23]. - Basic earnings per share decreased to CNY 0.33 from CNY 1.16 in the previous year, reflecting a decline of 71.6%[24]. Assets and Liabilities - Total assets increased by 87.15% to ¥1,750,214,044.04 compared to the end of the previous year[4]. - Current liabilities totaled CNY 361,297,027.18, an increase from CNY 232,322,638.51 at the beginning of the year, reflecting a rise of 55.55%[21]. - The company’s equity attributable to shareholders rose to CNY 1,325,581,310.21 from CNY 607,415,232.18, an increase of 118.05%[21]. - The company’s short-term borrowings increased to CNY 131,831,412.71 from CNY 66,031,939.85, reflecting a rise of 99.93%[21]. - Inventory levels increased to CNY 133,873,868.87 from CNY 90,904,932.59, representing an increase of 47.14%[20]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,950[11]. - The largest shareholder, Cai Danqun, holds 34.89% of shares, totaling 25,820,000 shares[11]. - The second-largest shareholder, Cai Shaoxin, holds 21.19% of shares, totaling 15,680,000 shares[11]. - The top 10 shareholders include entities with significant stakes, such as Yingde Zhongxing Investment Management Co., Ltd. with 6.76% (5,000,000 shares)[11]. - The total number of shares held by the top 10 unrestricted shareholders includes Zhang Xiu with 564,800 shares through a margin account[12]. - The company has a total of 25,820,000 shares held by Cai Danqun that are subject to lock-up until December 28, 2026[14]. - The company has a total of 5,000,000 shares held by Yingde Zhongxing that are also subject to lock-up until December 28, 2026[14]. - The company plans to release 550,000 shares from lock-up on June 27, 2024, held by Huatai Securities Asset Management[14]. - The company has a total of 1,350,000 shares held by Qiongcheng Huatao Zhi Ying No. 2 Investment Partnership that are subject to lock-up until June 27, 2024[14]. - The company has not disclosed any significant changes in restricted shares during the reporting period[13]. Cash Flow and Financing - Cash flow from financing activities surged by 1324% to ¥77,168.17 million, mainly due to funds raised from the IPO[9]. - Cash and cash equivalents increased significantly to CNY 191,240,047.19 from CNY 17,471,341.22 at the beginning of the year, representing an increase of 989.06%[19]. - Cash and cash equivalents at the end of the period increased to CNY 177,540,870.22 from CNY 23,427,900.90, showing a significant improvement in liquidity[26]. - The company raised CNY 785,325,000.00 through investment activities, indicating a strong capital influx[26]. Company Developments - The company established a wholly-owned subsidiary, Hubei Shengkang Chemical Co., Ltd., to invest in a new special chemical materials project on a 360-acre land in Yichang, Hubei[16]. - Fixed assets increased to CNY 425,635,687.69 from CNY 332,903,209.77, marking a growth of 27.83%[20]. Audit Status - The company has not undergone an audit for the Q3 report, indicating that the figures are unaudited[28].
广康生化(300804) - 2023 Q3 - 季度财报